Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $15.2 million.

  • Cumberland Pharmaceuticals' Cash & Equivalents fell 1298.62% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 1298.62%. This contributed to the annual value of $18.0 million for FY2024, which is 195.09% down from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Cash & Equivalents is $15.2 million, which was down 1298.62% from $16.1 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Cash & Equivalents registered a high of $27.0 million during Q4 2021, and its lowest value of $15.1 million during Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $18.2 million (2023), whereas its average is $19.3 million.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Cash & Equivalents tumbled by 3071.93% in 2022 and then surged by 1319.6% in 2024.
  • Cumberland Pharmaceuticals' Cash & Equivalents (Quarter) stood at $27.0 million in 2021, then dropped by 26.93% to $19.8 million in 2022, then fell by 7.27% to $18.3 million in 2023, then dropped by 1.95% to $18.0 million in 2024, then decreased by 15.41% to $15.2 million in 2025.
  • Its Cash & Equivalents was $15.2 million in Q3 2025, compared to $16.1 million in Q2 2025 and $15.1 million in Q1 2025.